Analysis of the delay components in the treatment of status epilepticus

Neurocritical Care

Volumn 19, Issue 1, 2013, Pages 10-18

  Kämppi, Leena ^a,d   Mustonen, Harri ^b   Soinila, Seppo ^c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d NONE   (Finland)

Author keywords

Convulsion; Epilepsy; Prehospital; Seizure

Indexed keywords

DIAZEPAM; FOSPHENYTOIN SODIUM; LORAZEPAM; MIDAZOLAM; PROPOFOL; THIOPENTAL; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; AMBULANCE; ARTICLE; BURST SUPPRESSION; CAUSE OF DEATH; CONSCIOUSNESS LEVEL; CONTROLLED STUDY; CONVULSION; DIAGNOSTIC TEST; ELECTROENCEPHALOGRAPHY; EMERGENCY CARE; EPILEPTIC STATE; FEMALE; FINLAND; HEALTH STATUS; HUMAN; INFORMATION PROCESSING; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT TRANSPORT; PNEUMONIA; PRIORITY JOURNAL; PROPOFOL INFUSION SYNDROME; QUANTITATIVE ANALYSIS; REHABILITATION CARE; RETROSPECTIVE STUDY; THERAPY DELAY; TIME TO TREATMENT; TREATMENT INDICATION; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

EID: 84880921374     PISSN: 15416933     EISSN: 15560961     Source Type: Journal    
DOI: 10.1007/s12028-013-9862-x     Document Type: Article

References (38)

1. Aminoff MJ, Simon RP. Status epilepticus: causes, clinical features and consequences in 98 patients. Am J Med. 1980;69:657-66. (Pubitemid 11241340)
2. Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia. 1994;35(1):27-34. (Pubitemid 24074462)
3. DeLorenzo RJ, Hauser WA, Towne AR, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996;46:1029-35. (Pubitemid 26134646)
4. Claassen J, Lokin JK, Fitzsimmons B-FM, Mendelsohn FA, Mayer SA. Predictors of functional disability and mortality after status epilepticus. Neurology. 2002;58:139-42. (Pubitemid 34041954)
5. Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol. 2005;62:1698-702. (Pubitemid 41626665)
6. Chin RFM, Neville BGR, Peckham C, Wade A, Bedford H, Scott RC. Treatment of community-onset, childhood convulsive status epilepticus: a prospective, population-based study. Lancet Neurol. 2008;7:696-703.
7. Neligan A, Shorvon SD. Prognostic factors, morbidity and mortality in tonic-clonic status epilepticus: a review. Epilepsy Res. 2011;93:1-10.
8. Legriel S, Mourvillier B, Bele N, et al. Outcomes in 140 critically ill patients with status epilepticus. Intensive Care Med. 2008;34:476-80.
9. Lotham E. The biochemical basis and pathophysiology of status epilepticus. Neurology. 1990;40(suppl):13-23.
10. DeGiorgio CM, Tomiyasu U, Gott PS, Treiman DM. Hippocampal pyramidal cell loss in human status epilepticus. Epilepsia. 1992;33:23-7.
11. Grabenstatter HL, Russek SJ, Brooks-Kayal AR. Molecular pathways controlling inhibitory receptor expression. Epilepsia. 2012;53(suppl 9):71-8.
12. Naylor DE, Liu H, Wasterlain CG. Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci. 2005;25(34):7724-33. (Pubitemid 41208643)
13. Mayer SA, Claassen J, Lokin J, Mendelson F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus: frequency, risk factors and impact on outcome. Arch Neurol. 2002;59:205-10. (Pubitemid 34240935)
14. Drislane FW, Blum AS, Lopez MR, Gautam S, Schomer DL. Duration on refractory status epilepticus and outcome: loss of prognostic utility after several hours. Epilepsia. 2009;50(6):1566-71.
15. Kalita J, Nair PP, Misra UK. A clinical, radiological and outcome study of status epilepticus from India. J Neurol. 2010;257:224-9.
16. Pellock JM, Marmarou A, DeLorenzo R. Time to treatment in prolonged seizure episodes. Epilepsy Behav. 2004;5:192-6. (Pubitemid 38461208)
17. Hesdorffer DC, Logroscino G, Cascino G, Annegers JF, Hauser WA. Insidence of status epilepticus in Rochester, Minnesota, 1965-1984. Neurology. 1998;50:735-41.
18. Coeytaux A, Jallon P, Galobardes B, Morabia A. Incidence of status epilepticus in French-speaking Switzerland (EPISTAR). Neurology. 2000;55:693-7.
19. Parviainen I, Uusaro A, Kälviäinen R, Kaukanen E, Mervaala E, Ruokonen E. High-dose thiopental in the treatment of refractory status epilepticus in intensive care unit. Neurology. 2002;59:1249-51. (Pubitemid 35192399)
20. Parviainen I, Uusaro A, Kälviäinen R, Mervaala E, Ruokonen E. Propofol in the treatment of refractory status epilepticus. Intensive Care Med. 2006;32:1075-9. (Pubitemid 43952725)
21. Lowenstein DH, Alldredge BK. Status epilepticus at an urban public hospital in the 1980s. Neurology. 1993;43:483-8. (Pubitemid 23088478)
22. Aranda A, Fuocart G, Ducasse JL, Grolleau S, McGonical A, Valton L. Generalized convulsive status epilepticus management in adults: a cohort study with evaluation of professional practice. Epilepsia. 2010;51(10):2159-67.
23. Trinka E. What is the evidence to use new intravenous AEDs in status epilepticus? Epilepsia. 2011;52(Suppl.8):35-8.
24. Misra UK, Kalita J, Maurya PK. Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. J Neurol. 2011;259:645-8.
25. Navarro V, Dagron C, Demeret S, et al. A prehospital randomized trial in convulsive status epilepticus. Epilepsia. 2012;52(Suppl.8):48-9.
26. Liu X, Wu Y, Chen Z, Ma M, Su L. A systematic review of randomized controlled trials on the therapeutic effect of intravenous sodium valproate in status epilepticus. Int J Neurosci. 2012;122:277-83.
27. Power KN, Flatten H, Gilhus NE, Engelsen BA. Propofol treatment in adult refractory status epilepticus. Mortality risk and outcome. Epilepsy Res. 2011;94:53-60.
28. Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systemic review. Epilepsia. 2002;43(2):146-53.
29. Rossetti AO, Milligan TA, Vulliémoz S, Michaelides C, Bertschi M, Lee JW. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care. 2010;14:4-10.
30. Iyer VN, Hoel R, Rabinstein AA. Propofol infusion syndrome in patients with refractory status epilepticus: an 11-year clinical experience. Crit Care Med. 2009;37(12):3024-30.
31. DeLorenzo RJ, Waterhouse EJ, Towne AR, et al. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia. 1998;39(8):833-40. (Pubitemid 128721651)
32. Holtkamp M, Othman J, Buchheim K, Meierkord H. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatr. 2005;76:534-9. (Pubitemid 40486579)
33. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134:2802-18.
34. Krishnamurthy KB, Drislane FW. Depth of EEG suppression and outcome in barbiturate anesthetic treatment of refractory status epilepticus. Epilepsia. 1999;40(6):759-62. (Pubitemid 29260716)
35. Meierkord H, Boon P, Engelsen B, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17:348-55.
36. Yaffe K, Lowenstein DH. Prognostic factors of pentobarbital therapy for refractory generalized status epilepticus. Neurology. 1993;43(5):895-900. (Pubitemid 23150558)
37. Krishnamurthy KB, Drislane FW. Relapse and survival after barbiturate anesthetic treatment of refractory status epilepticus. Epilepsia. 1996;37(9):863-7. (Pubitemid 26313732)
38. Holtkamp M, Othman J, Buchheim K, Masuhr F, Schielke E, Meierkord H. A "Malignant" of status epilepticus. Arch Neurol. 2005;62:1428-31. (Pubitemid 41352060)